Rituximab likely raises risk of hospital death in COVID-19 patients
December 2, 2021
In a retrospective study of hospitalized COVID-19 patients, “only 1 of 303 drugs examined, rituximab, was associated with an increased risk of in-hospital death ... both when used for rheumatologic as well as for cancer therapy.”
‘Misleading’ results in colchicine COVID-19 trials meta-analysis
November 23, 2021
“While the small studies are potentially insight providing, the large studies are the only ones worth giving our attention to in the context of the meta-analysis.”
Two swings, two misses with colchicine, Vascepa in COVID-19
September 1, 2021
The study cohorts varied from healthcare and public workers at high risk for infection to individuals already hospitalized with COVID-19.
Tocilizumab shortage continues as pandemic wears on
August 19, 2021
Emergency use authorization of tocilizumab for COVID-19 has led to a global shortage, but supplies for rheumatoid arthritis and other inflammatory conditions are faring better – for now.
Patients with rheumatic disease may experience flares after SARS-CoV-2 vaccination
June 28, 2021
A total of 202 SRD flares were reported by 165 patients (14.9%).
Mavrilimumab may aid severe COVID-19 recovery
June 10, 2021
The granulocyte/macrophage-colony stimulating factor (GM-CSF) blocker reduced the need for mechanical ventilation and death by day 29 versus placebo.
Hypertension worsened by commonly used prescription meds
May 6, 2021
Close to 20% of U.S. adults with hypertension are on a prescription drug, such as NSAIDs, known to raise blood pressure, creating an opportunity for drug substitution.
More evidence MIS-C is a delayed response to SARS-CoV-2
April 13, 2021
CDC analysis of the largest cohort of MIS-C cases in the United States to date shows three temporal peaks of diagnoses in the United States and further validates the “prevailing hypothesis that MIS-C is a postinfectious mediated disorder.”
COVID-19’s impact on lupus inpatients examined in study
March 24, 2021
Younger inpatients with COVID-19 and SLE showed higher mortality than did COVID-19 inpatients of similar age from the general population in a French epidemiologic study.
RECOVERY trial of COVID-19 treatments stops colchicine arm
March 8, 2021
Recruitment was halted for lack of efficacy in patients hospitalized with the disease.